Published in J Biol Chem on December 31, 2003
Mesenchymal origin of hepatic stellate cells, submesothelial cells, and perivascular mesenchymal cells during mouse liver development. Hepatology (2009) 2.51
Multigenerational epigenetic adaptation of the hepatic wound-healing response. Nat Med (2012) 2.28
MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology (2009) 2.17
Involvement of PPAR nuclear receptors in tissue injury and wound repair. J Clin Invest (2006) 1.55
VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology (2009) 1.47
Current and future anti-fibrotic therapies for chronic liver disease. Clin Liver Dis (2008) 1.39
Activation of PPARgamma is required for curcumin to induce apoptosis and to inhibit the expression of extracellular matrix genes in hepatic stellate cells in vitro. Biochem J (2004) 1.27
Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies. J Gastroenterol (2008) 1.23
Activation of peroxisome proliferator-activated receptor-gamma by curcumin blocks the signaling pathways for PDGF and EGF in hepatic stellate cells. Lab Invest (2008) 1.18
Inhibition of phosphatidylinositol 3-kinase signaling in hepatic stellate cells blocks the progression of hepatic fibrosis. Hepatology (2009) 1.17
Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation. Mol Cancer (2010) 1.16
Curcumin inhibits connective tissue growth factor gene expression in activated hepatic stellate cells in vitro by blocking NF-kappaB and ERK signalling. Br J Pharmacol (2007) 1.13
Hepatic stellate cell-derived delta-like homolog 1 (DLK1) protein in liver regeneration. J Biol Chem (2012) 1.07
The Necdin-Wnt pathway causes epigenetic peroxisome proliferator-activated receptor gamma repression in hepatic stellate cells. J Biol Chem (2010) 1.05
Lipid-induced hepatocyte-derived extracellular vesicles regulate hepatic stellate cell via microRNAs targeting PPAR-γ. Cell Mol Gastroenterol Hepatol (2015) 1.03
Rosmarinic acid and baicalin epigenetically derepress peroxisomal proliferator-activated receptor γ in hepatic stellate cells for their antifibrotic effect. Hepatology (2012) 1.01
The types of hepatic myofibroblasts contributing to liver fibrosis of different etiologies. Front Pharmacol (2014) 1.01
Daily genetic profiling indicates JAK/STAT signaling promotes early hepatic stellate cell transdifferentiation. World J Gastroenterol (2010) 1.01
Pigment epithelium-derived factor is an intrinsic antifibrosis factor targeting hepatic stellate cells. Am J Pathol (2010) 0.98
Expression of carboxylesterase and lipase genes in rat liver cell-types. Biochem Biophys Res Commun (2008) 0.97
Troglitazone suppresses transforming growth factor beta-mediated fibrogenesis in retinal pigment epithelial cells. Mol Vis (2008) 0.96
PPARs Mediate Lipid Signaling in Inflammation and Cancer. PPAR Res (2008) 0.96
Hepatic stellate cells and parasite-induced liver fibrosis. Parasit Vectors (2010) 0.95
Peroxisome proliferator-activated receptor γ: innate protection from excessive fibrogenesis and potential therapeutic target in systemic sclerosis. Curr Opin Rheumatol (2010) 0.95
MicroRNAs in fibrosis: opportunities and challenges. Arthritis Res Ther (2016) 0.93
Peroxisome proliferator-activated receptor-gamma inhibits transformed growth of non-small cell lung cancer cells through selective suppression of Snail. Neoplasia (2010) 0.92
Novel Molecular Mechanisms in the Development of Non-Alcoholic Steatohepatitis. Diabetes Metab J (2016) 0.92
Morphogens and hepatic stellate cell fate regulation in chronic liver disease. J Gastroenterol Hepatol (2012) 0.91
Pigment epithelium-derived factor 34-mer peptide prevents liver fibrosis and hepatic stellate cell activation through down-regulation of the PDGF receptor. PLoS One (2014) 0.89
Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats. Gut (2006) 0.89
Adiponectin regulation of stellate cell activation via PPARγ-dependent and -independent mechanisms. Am J Pathol (2011) 0.88
Rosiglitazone attenuates suppression of RXRalpha-dependent gene expression in inflamed liver. J Hepatol (2006) 0.88
Gene expression profiling of early hepatic stellate cell activation reveals a role for Igfbp3 in cell migration. PLoS One (2013) 0.87
Clinical application of transcriptional activators of bile salt transporters. Mol Aspects Med (2013) 0.87
Amplified inhibition of stellate cell activation pathways by PPAR-γ, RAR and RXR agonists. PLoS One (2013) 0.86
Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease. Gut (2016) 0.86
Additive inhibitory effect of experimentally induced hepatic cirrhosis by agonists of peroxisome proliferator activator receptor gamma and retinoic acid receptor. Dig Dis Sci (2008) 0.86
Pharmacological Intervention in Hepatic Stellate Cell Activation and Hepatic Fibrosis. Front Pharmacol (2016) 0.86
Telmisartan, an AT1 receptor blocker and a PPAR gamma activator, alleviates liver fibrosis induced experimentally by Schistosoma mansoni infection. Parasit Vectors (2013) 0.85
Retinoid X receptor and peroxisome proliferator-activated receptor-gamma agonists cooperate to inhibit matrix metalloproteinase gene expression. Arthritis Res Ther (2008) 0.84
Rosiglitazone prevents high glucose-induced vascular endothelial growth factor and collagen IV expression in cultured mesangial cells. Exp Diabetes Res (2009) 0.84
Adipogenesis and epicardial adipose tissue: a novel fate of the epicardium induced by mesenchymal transformation and PPARγ activation. Proc Natl Acad Sci U S A (2015) 0.84
The iron chelator deferoxamine causes activated hepatic stellate cells to become quiescent and to undergo apoptosis. J Gastroenterol (2007) 0.84
Peroxisome proliferator-activated receptor gamma down-regulates follistatin in intestinal epithelial cells through SP1. J Biol Chem (2008) 0.84
Enhancer of Zeste Homolog 2 Inhibition Attenuates Renal Fibrosis by Maintaining Smad7 and Phosphatase and Tensin Homolog Expression. J Am Soc Nephrol (2015) 0.84
Prevention and treatment of Schistosoma mansoni-induced liver fibrosis in mice. Inflammopharmacology (2011) 0.83
A peroxisome-proliferator activated receptor-gamma ligand could regulate the expression of leptin receptor on human hepatic stellate cells. Histochem Cell Biol (2007) 0.82
Differentiation potential of pancreatic fibroblastoid cells/stellate cells: effects of peroxisome proliferator-activated receptor gamma ligands. Int J Cell Biol (2011) 0.82
Effect of ligand of peroxisome proliferator-activated receptor gamma on the biological characters of hepatic stellate cells. World J Gastroenterol (2005) 0.81
Transcriptional regulation of methionine adenosyltransferase 2A by peroxisome proliferator-activated receptors in rat hepatic stellate cells. Hepatology (2012) 0.81
Mutant MMP-9 and HGF gene transfer enhance resolution of CCl4-induced liver fibrosis in rats: role of ASH1 and EZH2 methyltransferases repression. PLoS One (2014) 0.81
Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapies. Clin Gastroenterol Hepatol (2013) 0.80
Nuclear receptor profile in calvarial bone cells undergoing osteogenic versus adipogenic differentiation. J Cell Biochem (2008) 0.80
In vitro reversion of activated primary human hepatic stellate cells. Fibrogenesis Tissue Repair (2015) 0.79
Metabolic reprogramming and cell fate regulation in alcoholic liver disease. Pancreatology (2015) 0.79
Molecular Cues Guiding Matrix Stiffness in Liver Fibrosis. Biomed Res Int (2016) 0.78
A role for peroxisome proliferator-activated receptors in the immunopathology of schistosomiasis? PPAR Res (2011) 0.78
Transgenic expression of an altered angiotensin type I AT1 receptor resulting in marked modulation of vascular type I collagen. J Cell Physiol (2012) 0.78
Morphogen-related therapeutic targets for liver fibrosis. Clin Res Hepatol Gastroenterol (2015) 0.78
Senescence in hepatic stellate cells as a mechanism of liver fibrosis reversal: a putative synergy between retinoic acid and PPAR-gamma signalings. Clin Exp Med (2016) 0.77
Anti- and Protumorigenic Effects of PPARγ in Lung Cancer Progression: A Double-Edged Sword. PPAR Res (2012) 0.77
Thiazolidinediones and hepatic fibrosis: don't wait too long. Gut (2006) 0.77
New Approaches for Studying Alcoholic Liver Disease. Curr Pathobiol Rep (2014) 0.76
NHE1 deficiency in liver: implications for non-alcoholic fatty liver disease. Biochem Biophys Res Commun (2014) 0.75
Targeting EZH1 and EZH2 contributes to the suppression of fibrosis-associated genes by miR-214-3p in cardiac myofibroblasts. Oncotarget (2016) 0.75
Curcumin adds spice to the debate: lipid metabolism in liver disease. Br J Pharmacol (2009) 0.75
Curcumin targets multiple pathways to halt hepatic stellate cell activation: updated mechanisms in vitro and in vivo. Dig Dis Sci (2014) 0.75
Evolving Insights on Metabolism, Autophagy, and Epigenetics in Liver Myofibroblasts. Front Physiol (2016) 0.75
Wnt Pathway Stabilizes MeCP2 Protein to Repress PPAR-γ in Activation of Hepatic Stellate Cells. PLoS One (2016) 0.75
A Proof-of-Concept for Epigenetic Therapy of Tissue Fibrosis: Inhibition of Liver Fibrosis Progression by 3-Deazaneplanocin A. Mol Ther (2017) 0.75
The Role of PPARgamma in Hepatocellular Carcinoma. PPAR Res (2008) 0.75
Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol (2017) 0.75
Novel Anti-fibrotic Therapies. Front Pharmacol (2017) 0.75
Hepatitis C virus infection--pathobiology and implications for new therapeutic options. Dig Dis Sci (2007) 0.75
Human Protein Reference Database--2009 update. Nucleic Acids Res (2008) 21.25
Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc Natl Acad Sci U S A (2012) 3.90
Interaction of the hereditary hemochromatosis protein HFE with transferrin receptor 2 is required for transferrin-induced hepcidin expression. Cell Metab (2009) 3.78
NOTCH reprograms mitochondrial metabolism for proinflammatory macrophage activation. J Clin Invest (2015) 2.93
Critical role of the stress chaperone GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development. Cancer Res (2008) 2.81
Renal and extrarenal hemodynamic effects of furosemide in congestive heart failure after acute myocardial infarction. N Engl J Med (1973) 2.79
ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). J Am Coll Cardiol (1999) 2.58
Mechanism of corepressor binding and release from nuclear hormone receptors. Genes Dev (1999) 2.57
Mesenchymal origin of hepatic stellate cells, submesothelial cells, and perivascular mesenchymal cells during mouse liver development. Hepatology (2009) 2.51
Kupffer cell and interleukin-12-dependent loss of natural killer T cells in hepatosteatosis. Hepatology (2010) 2.48
Molecular mechanisms of hepatic fibrogenesis. J Gastroenterol Hepatol (2007) 2.24
Osteopontin deficiency does not prevent but promotes alcoholic neutrophilic hepatitis in mice. Hepatology (2014) 2.17
MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology (2009) 2.17
Paracrine regulation of angiogenesis and adipocyte differentiation during in vivo adipogenesis. Circ Res (2003) 2.12
DNase I-hypersensitive sites enhance alpha1(I) collagen gene expression in hepatic stellate cells. Hepatology (2003) 2.10
Mechanisms of liver fibrosis. Clin Chim Acta (2005) 2.09
Hemodynamic and metabolic responses to vasodilator therapy in acute myocardial infarction. Circulation (1973) 2.08
Toll-like receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog. Proc Natl Acad Sci U S A (2009) 2.07
StellaTUM: current consensus and discussion on pancreatic stellate cell research. Gut (2011) 2.07
Immediate and sustained hemodynamic and clinical improvement in chronic heart failure by an oral angiotensin-converting enzyme inhibitor. Circulation (1980) 2.02
Wnt antagonism inhibits hepatic stellate cell activation and liver fibrosis. Am J Physiol Gastrointest Liver Physiol (2007) 1.99
Septum transversum-derived mesothelium gives rise to hepatic stellate cells and perivascular mesenchymal cells in developing mouse liver. Hepatology (2011) 1.95
Role of transglutaminase 2 in liver injury via cross-linking and silencing of transcription factor Sp1. Gastroenterology (2009) 1.89
Electrocardiographic changes subsequent to artificial ventricular depolarization. Br Heart J (1969) 1.88
Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology (2003) 1.86
Adipogenic transcriptional regulation of hepatic stellate cells. J Biol Chem (2004) 1.84
Vasodilator treatment for acute and chronic heart failure. Br Heart J (1977) 1.84
Localization of iron metabolism-related mRNAs in rat liver indicate that HFE is expressed predominantly in hepatocytes. Blood (2003) 1.77
Heart-block following acute myocardial infarction. Treatment with demand and fixed-rate pacemakers. Lancet (1968) 1.77
The role of focal adhesion kinase-phosphatidylinositol 3-kinase-akt signaling in hepatic stellate cell proliferation and type I collagen expression. J Biol Chem (2002) 1.77
Comparison of transesophageal echocardiographic and scintigraphic estimates of left ventricular end-diastolic volume index and ejection fraction in patients following coronary artery bypass grafting. Anesthesiology (1990) 1.75
Steatohepatitis induced by intragastric overfeeding in mice. Hepatology (2005) 1.73
Ventricular contraction abnormalities in dilated cardiomyopathy: effect of biventricular pacing to correct interventricular dyssynchrony. J Am Coll Cardiol (2000) 1.73
Primary cirrhotic hepatocytes resist TGFbeta-induced apoptosis through a ROS-dependent mechanism. J Hepatol (2004) 1.72
Accumulation of hedgehog-responsive progenitors parallels alcoholic liver disease severity in mice and humans. Gastroenterology (2008) 1.71
Metabolic and hemodynamic consequences of sodium bicarbonate administration in patients with heart disease. Am J Med (1989) 1.70
The role of vasodilator therapy in heart failure. Prog Cardiovasc Dis (1977) 1.69
Liver X receptor signaling is a determinant of stellate cell activation and susceptibility to fibrotic liver disease. Gastroenterology (2010) 1.67
Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate. J Am Coll Cardiol (1994) 1.66
Heart failure therapy in evolution. Circulation (1996) 1.64
The influence of left ventricular filling pressure on atrial contribution to cardiac output. Am Heart J (1979) 1.63
Long-term digitalis therapy improves left ventricular function in heart failure. N Engl J Med (1980) 1.63
Polymorphous ventricular tachycardia associated with acute myocardial infarction. Circulation (1991) 1.61
Mesothelial cells give rise to hepatic stellate cells and myofibroblasts via mesothelial-mesenchymal transition in liver injury. Proc Natl Acad Sci U S A (2013) 1.59
Hemodynamic and metabolic effects of isosorbide dinitrate in chronic congestive heart failure. Am Heart J (1975) 1.58
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Detection and characterization of acute myocardial infarction in man with use of gated magnetic resonance. Circulation (1985) 1.55
Alterations in left ventricular function and coronary hemodynamics with captopril, hydralazine and prazosin in chronic ischemic heart failure: a comparative study. Circulation (1982) 1.54
The risk of pacing after infarction, and current recommendations. Lancet (1969) 1.50
Pathology of tropical appendicitis. J Clin Pathol (1989) 1.47
Medical therapy of acute myocardial infarction by application of hemodynamic subsets (first of two parts). N Engl J Med (1976) 1.45
Markers for transfusion-transmissible infections in north Indian voluntary and replacement blood donors: prevalence and trends 1989-1996. Vox Sang (1997) 1.44
Liver fibrosis: signals leading to the amplification of the fibrogenic hepatic stellate cell. Front Biosci (2003) 1.42
Testosterone relaxes rabbit coronary arteries and aorta. Circulation (1995) 1.42
Essential role of matrix metalloproteinases in interleukin-1-induced myofibroblastic activation of hepatic stellate cell in collagen. J Biol Chem (2003) 1.42
A critical role for GRP78/BiP in the tumor microenvironment for neovascularization during tumor growth and metastasis. Cancer Res (2011) 1.40
Interstudy reproducibility of dimensional and functional measurements between cine magnetic resonance studies in the morphologically abnormal left ventricle. Am Heart J (1990) 1.40
The noninvasive diagnosis of right ventricular infarction. Circulation (1978) 1.39
Synergistic steatohepatitis by moderate obesity and alcohol in mice despite increased adiponectin and p-AMPK. J Hepatol (2011) 1.39
Reciprocal regulation by TLR4 and TGF-β in tumor-initiating stem-like cells. J Clin Invest (2013) 1.37
Effects of vasodilator therapy for severe pump failure in acute myocardial infarction on short-term and late prognosis. Circulation (1976) 1.37
Toll-like receptor 4 mediates alcohol-induced steatohepatitis through bone marrow-derived and endogenous liver cells in mice. Alcohol Clin Exp Res (2011) 1.37
Beneficial effects of vasodilator agents in severe mitral regurgitation due to dysfunction of subvalvar apparatus. Circulation (1973) 1.36
SMAD and p38 MAPK signaling pathways independently regulate alpha1(I) collagen gene expression in unstimulated and transforming growth factor-beta-stimulated hepatic stellate cells. J Biol Chem (2005) 1.36
Long-term vasodilator therapy for heart failure: clinical response and its relationship to hemodynamic measurements. Circulation (1981) 1.35
Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats. Hepatology (2005) 1.34
Optimal level of filling pressure in the left side of the heart in acute myocardial infarction. N Engl J Med (1973) 1.32
S-adenosylmethionine in the chemoprevention and treatment of hepatocellular carcinoma in a rat model. Hepatology (2009) 1.32
Oral hydralazine therapy for chronic refractory heart failure. Circulation (1976) 1.30
Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol (1999) 1.30
Testosterone induces dilation of canine coronary conductance and resistance arteries in vivo. Circulation (1996) 1.30
Signaling role of intracellular iron in NF-kappaB activation. J Biol Chem (2003) 1.30
Medical therapy of acute myocardial infarction by application of hemodynamic subsets (second of two parts). N Engl J Med (1976) 1.28
Depression of left ventricular function due to acute myocardial ischemia and its reversal after aortocoronary saphenous-vein bypass. N Engl J Med (1972) 1.27
The cavity electrocardiogram in emergency artificial pacing. Postgrad Med J (1969) 1.27
Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver. Am J Physiol Gastrointest Liver Physiol (2003) 1.27
Emergency bypass surgery in impending and complicated acute myocardial infarction. Arch Surg (1972) 1.27
Influence of direct myocardial revascularization on left ventricular asynergy and function in patients with coronary heart disease. With and without previous myocardial infarction. Circulation (1973) 1.26
Wound healing activity of embelin isolated from the ethanol extract of leaves of Embelia ribes Burm. J Ethnopharmacol (2006) 1.26
Ethanol-induced expression of ET-1 and ET-BR in liver sinusoidal endothelial cells and human endothelial cells involves hypoxia-inducible factor-1alpha and microrNA-199. J Immunol (2009) 1.26
Fall of endocardial potentials after acute myocardial infarction. Lancet (1970) 1.26
A matrix metalloproteinase-9 activation cascade by hepatic stellate cells in trans-differentiation in the three-dimensional extracellular matrix. J Biol Chem (2007) 1.26
Hemojuvelin-neogenin interaction is required for bone morphogenic protein-4-induced hepcidin expression. J Biol Chem (2009) 1.24
Suppression of hepatic hepcidin expression in response to acute iron deprivation is associated with an increase of matriptase-2 protein. Blood (2010) 1.24
Activated natural killer T cells induce liver injury by Fas and tumor necrosis factor-alpha during alcohol consumption. Gastroenterology (2004) 1.21
LPS signaling enhances hepatic fibrogenesis caused by experimental cholestasis in mice. Am J Physiol Gastrointest Liver Physiol (2006) 1.20
c-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair. Hepatology (2010) 1.20
Mouse intragastric infusion (iG) model. Nat Protoc (2012) 1.19